CTN :43492303
06 Feb, 2026
55.94 Crore
Tender For corrigendum : supply of essential drugs under sdl. - colistimethate sodium ext-red-selected">injection 1 million iu powd
er for solutionvial, farop
en
em tabl
et 200mg 1x6, polymixin b
ext-r
ed-s
el
ect
ed">inj
ection 500000 iuvial, tig
ecyclin
e ext-r
ed-s
el
ect
ed">inj
ection 50mgvial, t
eicoplanin
ext-r
ed-s
el
ect
ed">inj
ection 400mgvial, valganciclovir tabl
et 450 mg1x2, voriconazol
e tabl
et 200 mg 1x4, nicorandil tabl
et 10 mg1x10/1x20, isopr
enalin
e ext-r
ed-s
el
ect
ed">inj
ection 2mg1 ml amp, octr
eotid
e ext-r
ed-s
el
ect
ed">inj
ection 100 mcg/ml1 ml amp, ac
etylsalicylic acid (a)+clopidogr
el(b)tabl
et (a)150 mg+(b)75 mg1x10, r
et
eplas
e ext-r
ed-s
el
ect
ed">inj
ection 18 mg vial, rifaximin
e tabl
et 550mg1x10,
empagliflozin tabl
et 10 mg1x10, linagliptin
e tabl
et 5mg1x10, sitagliptin capsul
e 50 mg1x7/1x10, r
ecombinant growth
ext-r
ed-s
el
ect
ed">hormon
e ext-r
ed-s
el
ect
ed">inj
ection p
er iuvial/pfs, ranibizumab
ext-r
ed-s
el
ect
ed">inj
ection 10 mg/ml (2.3 mg/0.23 ml p
er vial)vial/amp, i.v fat
emulsion infusion 20%100 ml bottl
e, human albumin infusion 20%100 ml bottl
e /bag, multi-
el
ectrolyt
e in 5% d
extros
einfusion 500 ml ffs plastic bottl
e, r
ecombinant factor viia
ext-r
ed-s
el
ect
ed">inj
ection 1mgvial, rurioctocog alfa p
egol
ext-r
ed-s
el
ect
ed">inj
ection 500 iu.vial/pfs,
eptacog alfa (activat
ed r
ecombinant coagulation factor viia)
ext-r
ed-s
el
ect
ed">inj
ection 1 mgvial/pfs, luspat
erc
ept
ext-r
ed-s
el
ect
ed">inj
ection 25 mg.vial, d
ef
erasirox tabl
et 400mg1x6/1x10, d
ef
erasirox tabl
et 100mg1x6/1x10, olanzapin
e tabl
et 10 mg1x10, qu
etiapin
e tabl
et 50mg1x10, gabap
entin capsul
e 300 mg1x10, dutast
erid
e soft g
elatin capsul
e 0.5mg1x10, tamsulosin tabl
et 0.4mg mr1x10, silodosin tabl
et 8mg1x10, s
ev
elam
er tabl
et 400 mg 1x10, abirat
eron
e ac
et
eat
etabl
et 250 mg120 tabl
ets in a bottl
e, anti thymocyt
e globulin
e ext-r
ed-s
el
ect
ed">inj
ection 250 mg.5 ml glass vial, azacitidin
e ext-r
ed-s
el
ect
ed">inj
ection 100 mgvial, cisplatin
ext-r
ed-s
el
ect
ed">inj
ection 50mgvial, crizotinib capsul
e 250mg1x10, cytarabin
e ext-r
ed-s
el
ect
ed">inj
ection 100mgvial, cytarabin
e ext-r
ed-s
el
ect
ed">inj
ection 500mgvial, dasatinib tabl
et 50 mg60 tabs contain
er, d
ecitabin
e ext-r
ed-s
el
ect
ed">inj
ection 30 mgvial, daratumumab
ext-r
ed-s
el
ect
ed">inj
ection 400 mg/20 ml vial, daratumumab + hyaluronidas
e ext-r
ed-s
el
ect
ed">inj
ection 1,800 mg daratumumab and 30,000 units hyaluronidas
e p
er 15 ml (subcutan
eous)singl
e-dos
e vial., d
egar
elix
ext-r
ed-s
el
ect
ed">inj
ection 80mgvial,
enzalutamid
e capsul
e 40 mg 1x28,
erlotinib tabl
et 150mg1x10,
ev
erolimus tabl
et 0.25 mg 1x10, ibrutinib capsul
e 140mg120 capsul
e in a bottl
e, ifosamid
e ext-r
ed-s
el
ect
ed">inj
ection ifosamid
e 1 gm with m
esna 200 mgcombi pack of 20 ml vial of ifosamid
e & 3x2 ml amps of m
esna,
each 2 ml amp contains 200 mg m
esna., l
eucovorin
ext-r
ed-s
el
ect
ed">inj
ection 50mg/5 mlvial/ampoul
e, l
euprolid
e ext-r
ed-s
el
ect
ed">inj
ection 3.75mgvial, nilotinib tabl
et/capsul
e 150 mg1x7/1x14, nilotinib tabl
et/capsul
e 200mg1x7/1x14, paclit
exal
ext-r
ed-s
el
ect
ed">inj
ection 260 mgvial, palbociclib tabl
et/capsul
e 75 mg1x7/1x21, palbociclib tabl
et/capsul
e 125 mg1x7/1x21, pazopanib tabl
et 400mg30 tabl
ets in a bottl
e, ribociclib tabl
et 200 mg1x21, ruxolitinibtabl
et 20 mg1x10/1x14, sorafinibtab 200mg120 tabl
ets in a bottl
e, sunitinib tabl
et/capsul
e 12.5mg1x7, b
evacizumab
ext-r
ed-s
el
ect
ed">inj
ection 100mgvial, onas
emnog
en
e ab
eparvov
ec susp
ension for iv infusion 2.0 1013 v
ector g
enom
es/mlvial, asciminib tabl
et 40 mg.30 tabl
ets in a bottl
e, m
epolizumab
ext-r
ed-s
el
ect
ed">inj
ection 100 mg vial, t
eclistamab
ext-r
ed-s
el
ect
ed">inj
ection 30 mg/3ml (10 mg/ml)vial, obinutuzumab
ext-r
ed-s
el
ect
ed">inj
ection 1,000 mg/40 ml (25 mg/ml) vial, polatuzumab v
edotin
ext-r
ed-s
el
ect
ed">inj
ection 140 mg/vial.vial, at
ezolizumab
ext-r
ed-s
el
ect
ed">inj
ection 1,200 mg/20 ml (60 mg/ml) vial, sp
esolimab
ext-r
ed-s
el
ect
ed">inj
ection 450 mg/7.5 ml (60 mg/ml) vial, p
embrolizumab
ext-r
ed-s
el
ect
ed">inj
ection 100 mg/4 ml (25 mg/ml)vial, ocr
elizumab
ext-r
ed-s
el
ect
ed">inj
ection 300 mg/10 mlvial, ust
ekinumab
ext-r
ed-s
el
ect
ed">inj
ection 130 mg/26 ml (5 mg/ml)vial, b
enralizumab
ext-r
ed-s
el
ect
ed">inj
ection 30 mg/1 mlpfs, faricimab
ext-r
ed-s
el
ect
ed">inj
ection 6 mg/0.05 ml (120 mg/ml)vial, acalabrutinib capsul
e 100 mg30 capsul
e in a bottl
e, inotuzumab ozogamicin
ext-r
ed-s
el
ect
ed">inj
ection 1 mg/vialvial, bupr
enorphin
e (a) + naloxon
e (b)tabl
et (sub-lingual) 2 mg (a) + 0.5 mg (b)1x10,
etan
erc
ept
ext-r
ed-s
el
ect
ed">inj
ection 25 mgpfs/vial,
etan
erc
ept
ext-r
ed-s
el
ect
ed">inj
ection 50 mgpfs/vial, alirocumab
ext-r
ed-s
el
ect
ed">inj
ection 75 mg/ml.pfs,
evolocumab
ext-r
ed-s
el
ect
ed">inj
ection 140 mg/ml.pfs, inclisiran
ext-r
ed-s
el
ect
ed">inj
ection 284 mg/1.5 ml.pfs, risdiplam tabl
et 5 mg30 tabl
ets in a bottl
e, risdiplam powd
er for oral solution 0.75 mg/ml aft
er r
econstitution.80 ml bottl
e, fulv
estrant
ext-r
ed-s
el
ect
ed">inj
ection 250 mgvial/pfs, r
ecombinant human int
erf
eron b
eta-1a in